A Broader Look at Autoimmune Disease Research
Autoimmune diseases occur when the immune system mistakenly attacks the body’s own tissues. These conditions can affect many areas of the body, including the joints, skin, digestive tract, nervous system, and internal organs.
Examples include Crohn’s disease, systemic lupus erythematosus, rheumatoid arthritis, scleroderma, psoriasis, ulcerative colitis, and Sjögren’s syndrome. While each condition is different, many share common features such as chronic inflammation, immune imbalance, tissue damage, and cycles of flare-ups and remission.
Current treatments often focus on reducing inflammation and calming the immune system. These approaches can be helpful, but some patients may not respond well, may lose response over time, or may continue to experience tissue damage. Because of this, researchers are studying whether stem cell-based therapies may offer another way to support immune balance and tissue repair.
Why Stem Cells Are Being Studied
Stem cell therapy is being explored in autoimmune disease research because certain stem cells may help influence immune activity and support a healthier inflammatory response.
Mesenchymal stem cells, or MSCs, are one of the most studied cell types in this field. MSCs release signaling molecules that may help regulate overactive immune responses, support immune tolerance, and encourage tissue repair. This is especially important in autoimmune diseases, where the immune system may remain chronically activated.
Other cell types, such as hematopoietic stem cells, are also being studied. Hematopoietic stem cell transplantation, or HSCT, is often researched in more severe autoimmune disease settings because it may help “reset” parts of the immune system after intensive treatment.
Overall, the goal of this research is not only symptom control, but also a better understanding of whether stem cell-based approaches can help restore immune balance and support recovery in damaged tissues.
What This Study Reviewed
This 2025 systematic review analyzed global clinical trials involving stem cell therapy for autoimmune diseases. Instead of focusing on one disease or one treatment, the researchers looked at the larger clinical trial landscape.
The authors searched Trialtrove and cross-checked results with ClinicalTrials.gov and the EU Clinical Trials Register. After screening, they included 244 interventional clinical trials conducted between 2006 and 2025.
The review looked at several key areas, including:
- Which autoimmune diseases are being studied most often
- What types of stem cells are being used
- Where trials are being conducted
- How trials are funded
- What mechanisms researchers are targeting
- What challenges remain before broader clinical use
This type of review is helpful because it shows where the field is currently strongest and where more research is still needed.
What the Trial Landscape Shows
The study found that clinical trial activity has grown over time, although most trials are still in the earlier stages of research.
Crohn’s disease was the most studied autoimmune condition, with 85 trials. Systemic lupus erythematosus, or SLE, followed with 36 trials, and scleroderma had 32 trials. Together, these conditions made up a large portion of the current research landscape.
Most studies were Phase I or Phase II trials, meaning researchers are still mainly evaluating safety, dosing, feasibility, and early signs of effectiveness. According to the review, 83.6% of the included trials were in Phase I–II, showing that stem cell therapy for autoimmune diseases is still an emerging clinical field.
The study also found that research is concentrated in certain parts of the world. The United States and China had the highest number of trials, followed by countries such as Spain, South Korea, Belgium, and France. Academic institutions were the most common funding source, supporting nearly half of the included trials.
Key Areas of Scientific Interest
Across the trials, researchers found that stem cell therapies were mainly being studied for immune system modulation, growth factor-mediated tissue repair, and other repair-supportive biological effects.
Immune modulation was the most common area of interest. This makes sense because autoimmune diseases are rooted in immune system imbalance. A therapy that may help calm excessive immune activity or support immune tolerance could be valuable in conditions where inflammation drives long-term tissue damage.
Tissue repair was another major focus. In autoimmune diseases, damage can continue even after inflammation is reduced. For example, Crohn’s disease may involve injury to intestinal tissue, while scleroderma can involve fibrosis and vascular changes. Stem cell-based approaches are being studied for their potential to support repair-related signaling in these damaged tissues.
The review also found that MSCs were the most commonly used stem cell type. MSCs from bone marrow, umbilical cord, adipose tissue, and other sources accounted for 178 trials, or 73.0% of the total. The authors noted that umbilical cord-derived MSCs were commonly studied in SLE trials, while hematopoietic stem cells were a major focus in scleroderma research.
Why These Findings Matter
This review is important because it shows that stem cell therapy for autoimmune diseases is being actively studied in clinical trials around the world. It also gives a clearer picture of which diseases, cell types, and research directions are receiving the most attention.
At the same time, the study makes it clear that the field is still developing. Many trials are early-stage, and there is still a need for larger, well-designed studies that can better answer questions about safety, consistency, long-term outcomes, and which patients may benefit most.
For regenerative medicine, the findings highlight two major themes: immune regulation and tissue repair. Autoimmune diseases often involve both overactive immune signaling and damage to tissues or organs. Stem cell-based therapies are being studied because they may influence both processes, making them an important area for continued investigation.
Challenges and Future Directions
Although the clinical trial landscape is promising, the authors noted several challenges. One major issue is standardization. Stem cell therapies can vary depending on the cell source, preparation method, dose, delivery route, culture process, and quality control standards.
These differences can make it difficult to compare results across studies. Future research will need more consistent protocols so scientists can better understand which approaches are safest and most effective.
The review also pointed to the need for more international collaboration, stronger clinical trial design, improved cell engineering, precision medicine approaches, and better long-term follow-up.
Takeaway
This systematic review shows that stem cell therapy is an active and growing area of autoimmune disease research. Across 244 global clinical trials, researchers are mainly studying how stem cell-based therapies may help regulate the immune system, support tissue repair, and address inflammatory damage.
While the field is still early and more research is needed, the findings highlight the promise of regenerative medicine for complex immune-related conditions. As clinical trials continue to improve, stem cell-based approaches may help shape future strategies focused on immune balance, repair, and long-term disease support.
Source
Chen Y, Li X, Zhang J, Peng J, Huang F, Bao J, Fan Y, Huang S. Global clinical trials on stem cell therapy for autoimmune diseases: trends and future directions. Frontiers in Immunology. 2025 Jul 24;16:1616231. doi: 10.3389/fimmu.2025.1616231. Available from: https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2025.1616231/full
Related Treatment Pages